Clinical trials: Social Adjustment
Parkinson's Disease
Psychiatry Study: Parkinson Disease
Main objective: To assess the impact of a structured program of preoperative cognitive remediation on postoperative social adaptation in patients suffering from Parkinson's disease profiting from bilateral subthalamic nucleus…
- Trial name
- NCT02893449
- Testing
- Social adaptation, Intensive care management, Deep brain stimulation
- Where
- 3 sites in France
- Volunteers
- 73 people
- Sponsor
- Central Hospital, Nancy, France
Schizophrenia, Schizoaffective Disorder
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, psychotic symptoms and social functioning in schizophrenia.
- Trial name
- OTS-12WK (NCT01394471)
- Testing
- Intranasal Oxytocin Spray
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of North Carolina, Chapel Hill
Hearing Loss, Stress
Clinical Trial of the "Living Well With Hearing Loss Workshop"
This study evaluates whether a 2 hour group session, "The Living Well with Hearing Loss Workshop," can successfully teach hard of hearing people how to best use hearing aids and a variety of personal skills to compensate for the…
- Trial name
- NCT00323427
- Testing
- The Living Well with Hearing Loss Workshop, hearing aid services
- Where
- 2 sites in United States
- Volunteers
- 135 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
Relapse Prevention in First Episode Schizophrenia: a 5 Year Trial
Objective: to evaluate the effectiveness of specialised and sustained intervention with or without parent groups during the initial phase of schizophrenia or related disorders on relapse prevention Methods: A three conditions…
- Trial name
- NCT01936220
- Testing
- Continuity of specialized care, Parent groups combined with Continuity of Specialized care, Discontinuity of care, non specialised care
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Indication for Modification of Patient Cognitive Status
Efficacy of Repyflec Cognitive Remediation Group Training in Schizophrenia
The purpose of this study was to develop an integrative intervention for schizophrenia taking into account previous efficacious therapies.
- Trial name
- NCT01279070
- Testing
- Repyflec cognitive remediation training
- Where
- Spain
- Volunteers
- 62 people
- Sponsor
- Fundació Sant Joan de Déu
Schizophrenia
Compensatory Strategies Applied to Cognitive Impairment in Schizophrenia
The purpose of this study is to determine whether Cognitive Adaptation Training are effective in comparison with conventional treatment, focusing on social functions, symptoms, relapse, re-hospitalisation, and quality of life in…
- Trial name
- CAT-Denmark (NCT01055509)
- Testing
- Cognitive Adaptation Training
- Where
- 3 sites in Denmark
- Volunteers
- 65 people
- Sponsor
- University of Southern Denmark
Post Traumatic Stress Disorder
A Pilot Study of Deep Brain Stimulation of the Amygdala for Treatment-Refractory Combat Post-Traumatic Stress Disorder
The purpose of this study is to determine whether deep brain stimulation of the basolateral nucleus (BLn) of the amygdala, on both sides of the brain, can safely reduce symptoms of post-traumatic stress disorder (PTSD) in combat…
- Trial name
- ADIP (NCT01658748)
- Testing
- Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS, Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
Subjective Well Being of Schizophrenic Patients in Greece
Non-interventional study aiming to provide data on the subjective effects of antipsychotic medication assessing subjective well-being and global functioning of patients with Schizophrenia under antipsychotic medication.
- Trial name
- AURA (NCT00857064)
- Where
- 24 sites in Greece
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Prodromal Schizophrenia, Prodromal Psychosis
Aripiprazole Treatment of the Prodrome
The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects.
- Trial name
- NCT00169949
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Bipolar Disorder
Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers
Cross - Sectional study requiring one visit at the investigators office for the data collection. Target Group: Patients that suffer from Bipolar Disorder Type 1.
- Trial name
- DIDAXI (NCT00691353)
- Where
- 20 sites in Greece
- Volunteers
- 540 people
- Sponsor
- AstraZeneca
Attention Deficit Hyperactivity Disorder
Further Studies of Attention Deficit Disorder - Residual Type (RT)
The first phase was a double-blind crossover design of methylphenidate in the treatment of adult ADHD. The second phase consisted of an open-label extension trial of methylphenidate in adult ADHD.
- Trial name
- NCT00693212
- Testing
- methylphenidate
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- University of Utah
Bipolar Disorder
Psychoeducation Versus Cognitive-Behavioral Therapy in Bipolar Disorder
To examine the impact of cognitive-behavioural therapy on both the episodic and functional outcome of bipolar disorder, in combination with pharmacotherapy. Primary Hypothesis is twofold: 1.
- Trial name
- NCT00188838
- Testing
- Psychoeduction, Cognitive-Behavioral Therapy
- Where
- 6 sites in Canada
- Volunteers
- 210 people
- Sponsor
- University Health Network, Toronto